201 related articles for article (PubMed ID: 28938966)
1. High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3.
Waksman R; Bakris GL; Steinvil A; Garcia-Garcia H; Brown AL; DiFilippo W; Scott T; Singh J; DeBruin V; Jones D; Jolivette D; Bhatt DL
Am Heart J; 2017 Oct; 192():76-84. PubMed ID: 28938966
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
Bhatt DL; Vaduganathan M; Kandzari DE; Leon MB; Rocha-Singh K; Townsend RR; Katzen BT; Oparil S; Brar S; DeBruin V; Fahy M; Bakris GL;
Lancet; 2022 Oct; 400(10361):1405-1416. PubMed ID: 36130612
[TBL] [Abstract][Full Text] [Related]
3. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial.
Bakris GL; Townsend RR; Flack JM; Brar S; Cohen SA; D'Agostino R; Kandzari DE; Katzen BT; Leon MB; Mauri L; Negoita M; O'Neill WW; Oparil S; Rocha-Singh K; Bhatt DL;
J Am Coll Cardiol; 2015 Apr; 65(13):1314-1321. PubMed ID: 25835443
[TBL] [Abstract][Full Text] [Related]
4. SYMPLICITY HTN-Japan - First Randomized Controlled Trial of Catheter-Based Renal Denervation in Asian Patients - .
Kario K; Ogawa H; Okumura K; Okura T; Saito S; Ueno T; Haskin R; Negoita M; Shimada K;
Circ J; 2015; 79(6):1222-9. PubMed ID: 25912693
[TBL] [Abstract][Full Text] [Related]
5. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension.
Fadl Elmula FE; Hoffmann P; Larstorp AC; Fossum E; Brekke M; Kjeldsen SE; Gjønnæss E; Hjørnholm U; Kjaer VN; Rostrup M; Os I; Stenehjem A; Høieggen A
Hypertension; 2014 May; 63(5):991-9. PubMed ID: 24591332
[TBL] [Abstract][Full Text] [Related]
6. Sufficient and Persistent Blood Pressure Reduction in the Final Long-Term Results From SYMPLICITY HTN-Japan - Safety and Efficacy of Renal Denervation at 3 Years.
Kario K; Yamamoto E; Tomita H; Okura T; Saito S; Ueno T; Yasuhara D; Shimada K;
Circ J; 2019 Feb; 83(3):622-629. PubMed ID: 30760655
[TBL] [Abstract][Full Text] [Related]
7. Individual-patient visit-by-visit office and ambulatory blood pressure measurements over 24months in patients undergoing renal denervation for hypertension.
Lambert T; Gammer V; Nahler A; Blessberger H; Kammler J; Grund M; Kerschner K; Buchmayr G; Saleh K; Kypta A; Hönig S; Wichert-Schmitt B; Schwarz S; Sihorsch K; Reiter C; Steinwender C
Int J Cardiol; 2015 Feb; 181():96-101. PubMed ID: 25497527
[TBL] [Abstract][Full Text] [Related]
8. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan.
Kario K; Bhatt DL; Brar S; Cohen SA; Fahy M; Bakris GL
Hypertension; 2015 Dec; 66(6):1130-7. PubMed ID: 26558819
[TBL] [Abstract][Full Text] [Related]
9. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension.
Mahfoud F; Ukena C; Schmieder RE; Cremers B; Rump LC; Vonend O; Weil J; Schmidt M; Hoppe UC; Zeller T; Bauer A; Ott C; Blessing E; Sobotka PA; Krum H; Schlaich M; Esler M; Böhm M
Circulation; 2013 Jul; 128(2):132-40. PubMed ID: 23780578
[TBL] [Abstract][Full Text] [Related]
10. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3.
Bakris GL; Townsend RR; Liu M; Cohen SA; D'Agostino R; Flack JM; Kandzari DE; Katzen BT; Leon MB; Mauri L; Negoita M; O'Neill WW; Oparil S; Rocha-Singh K; Bhatt DL;
J Am Coll Cardiol; 2014 Sep; 64(11):1071-8. PubMed ID: 24858423
[TBL] [Abstract][Full Text] [Related]
11. Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the "end of the road" for renal denervation?
Epstein M; de Marchena E
J Am Soc Hypertens; 2015 Feb; 9(2):140-9. PubMed ID: 25649995
[TBL] [Abstract][Full Text] [Related]
12. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.
Kandzari DE; Bhatt DL; Brar S; Devireddy CM; Esler M; Fahy M; Flack JM; Katzen BT; Lea J; Lee DP; Leon MB; Ma A; Massaro J; Mauri L; Oparil S; O'Neill WW; Patel MR; Rocha-Singh K; Sobotka PA; Svetkey L; Townsend RR; Bakris GL
Eur Heart J; 2015 Jan; 36(4):219-27. PubMed ID: 25400162
[TBL] [Abstract][Full Text] [Related]
13. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.
Townsend RR; Mahfoud F; Kandzari DE; Kario K; Pocock S; Weber MA; Ewen S; Tsioufis K; Tousoulis D; Sharp ASP; Watkinson AF; Schmieder RE; Schmid A; Choi JW; East C; Walton A; Hopper I; Cohen DL; Wilensky R; Lee DP; Ma A; Devireddy CM; Lea JP; Lurz PC; Fengler K; Davies J; Chapman N; Cohen SA; DeBruin V; Fahy M; Jones DE; Rothman M; Böhm M;
Lancet; 2017 Nov; 390(10108):2160-2170. PubMed ID: 28859944
[TBL] [Abstract][Full Text] [Related]
14. Impact of Antihypertensive Medication Changes After Renal Denervation Among Different Patient Groups: SPYRAL HTN-ON MED.
Townsend RR; Ferdinand KC; Kandzari DE; Kario K; Mahfoud F; Weber MA; Schmieder RE; Pocock S; Tsioufis K; David S; Steigerwalt S; Walton A; Hopper I; Bertolet B; Sharif F; Fengler K; Fahy M; Hettrick DA; Brar S; Böhm M
Hypertension; 2024 May; 81(5):1095-1105. PubMed ID: 38314554
[TBL] [Abstract][Full Text] [Related]
15. Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial.
Kario K; Mahfoud F; Kandzari DE; Townsend RR; Weber MA; Schmieder RE; Tsioufis K; Pocock S; Brar S; Hettrick DA; Fahy M; Böhm M
Hypertens Res; 2023 Jan; 46(1):280-288. PubMed ID: 36241705
[TBL] [Abstract][Full Text] [Related]
16. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs.
Mauri L; Kario K; Basile J; Daemen J; Davies J; Kirtane AJ; Mahfoud F; Schmieder RE; Weber M; Nanto S; Azizi M
Am Heart J; 2018 Jan; 195():115-129. PubMed ID: 29224639
[TBL] [Abstract][Full Text] [Related]
17. Assessment of hypertension control and clinical course of patients excluded from the SYMPLICITY HTN-3 trial.
Yerasi C; Baker NC; Jonnalagadda AK; Torguson R; Singh S; Vies J; Waksman R
J Am Soc Hypertens; 2015 Dec; 9(12):959-65. PubMed ID: 26687550
[TBL] [Abstract][Full Text] [Related]
18. 12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation.
Azizi M; Daemen J; Lobo MD; Mahfoud F; Sharp ASP; Schmieder RE; Wang Y; Saxena M; Lurz P; Sayer J; Bloch MJ; Basile J; Weber MA; Rump LC; Levy T; Sapoval M; Sanghvi K; Rader F; Fisher NDL; Gosse P; Abraham J; Claude L; Barman NC; McClure CK; Liu Y; Kirtane AJ;
JACC Cardiovasc Interv; 2020 Dec; 13(24):2922-2933. PubMed ID: 33357531
[TBL] [Abstract][Full Text] [Related]
19. Influence of pseudo-resistance on the effect of renal denervation on 24-hour ambulatory blood pressure levels.
Lambert T; Nahler A; Reiter C; Gammer V; Blessberger H; Kammler J; Grund M; Saleh K; Schwarz S; Steinwender C
Catheter Cardiovasc Interv; 2015 Sep; 86(3):E126-30. PubMed ID: 26033366
[TBL] [Abstract][Full Text] [Related]
20. Renal denervation in moderate treatment-resistant hypertension.
Ott C; Mahfoud F; Schmid A; Ditting T; Sobotka PA; Veelken R; Spies A; Ukena C; Laufs U; Uder M; Böhm M; Schmieder RE
J Am Coll Cardiol; 2013 Nov; 62(20):1880-6. PubMed ID: 23850901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
